This result replicates that of previous research regarding the role of CRP as a predictive indicator for the malignant potential and prognosis in various other cancers and suggests several possibilities: (1) preoperative elevations of CRP indicate a poor outcome in myeloma patients, or (2) bone involvement needing surgery is a significant adverse factor. This evidence concerns the gene CRP and plasma cell myeloma.